TIM-3 (T cell immunoglobulin and mucin domain-3) is a 60 kDa member of the TIM family of immune regulating molecules. TIMs are type I transmembrane glycoproteins with one Ig-like V-type domain and a Ser/Thr-rich mucin stalk (1-3). There are three TIM genes in human and eight in mouse. Mature mouse TIM-3 consists of a 174 amino acid (aa) extracellular domain (ECD), a 21 aa transmembrane segment (TM), and a 67 aa cytoplasmic tail (4). Two alternately spliced isoforms have been reported in mouse which lack either the TM or both the TM and mucin regions (5, 6). Within the ECD, mouse TIM-3 shares 58% and 74% aa sequence identity with human and rat TIM-3, respectively. TIM-3 is specifically expressed on Th1 cells whereas TIM-1 and TIM-2 are expressed on Th2 cells. In chronic inflammation, autoimmune disorders, and some cancers, TIM-3 is upregulated on several other hematopoietic cell types and on hippocampal neurons (9-12). The glycosylated Ig domain of TIM-3 binds cell-associated galectin-9 which induces TIM-3 Tyr phosphorylation and proapoptotic signaling (10, 13). TIM-3 functions as a negative regulator of Th1 cell activity. Its blockade results in increased IFN-gamma production, Th1 cell proliferation, and cytotoxicity (5, 7, 12, 14). TIM-3 may play a role in regulatory T cell development (7), inflammation (15), and immune tolerance (5, 13, 14). Soluble mouse TIM-3 has been shown to inhibit anti-tumor effector T cell responses and to enhance autoimmune reactions (6, 7).
Key Product Details
Validated by
Species Reactivity
Validated:
Cited:
Applications
Validated:
Cited:
Label
Antibody Source
Product Specifications
Immunogen
Leu22-Arg191
Accession # AAL65156
Specificity
Clonality
Host
Isotype
Scientific Data Images for Mouse TIM‑3 Antibody
Detection of Mouse TIM‑3 by Western Blot.
Western blot shows lysates of RAW 264.7 mouse monocyte/macrophage cell line. PVDF membrane was probed with 2 µg/mL of Goat Anti-Mouse TIM-3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1529) followed by HRP-conjugated Anti-Goat IgG Secondary Antibody (Catalog # HAF017). A specific band was detected for TIM-3 at approximately 45-70 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 1.
TIM‑3 in Mouse Spleen.
TIM‑3 was detected in immersion fixed paraffin-embedded sections of mouse spleen using Goat Anti-Mouse TIM‑3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1529) at 3 µg/mL for 1 hour at room temperature followed by incubation with the Anti-Goat IgG VisUCyte™ HRP Polymer Antibody (VC004). Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (CTS013). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue). Specific staining was localized to lymphocytes. Staining was performed using our protocol for IHC Staining with VisUCyte HRP Polymer Detection Reagents.
Detection of Mouse TIM-3 by Immunohistochemistry
Blocking TIM-3 significantly reduces brain injury after hypoxia-ischaemia.(a) Representative images of TTC-stained brain slices from H/I mice treated with 100 μg of IgG (n=12) or anti-TIM-3 antibody (n=12). The infarct volume was quantified with Image J analyser and expressed as a percentage of the damaged ipsilateral hemisphere. (b) Representative magnetic resonance images (MRIs) from TIM-3-antibody-treated mice (n=4) and IgG-treated mice (n=4) at 24 h post-H/I. (c) Representative T2 images from TIM-3-antibody-treated mice (n=4) and IgG-treated mice (n=4) after H/I. (d) The extent of the oedema formation was obtained from the T2-weighted MRI images and ADC map. (e) Representative confocal microscopic images of immunohistochemical staining for NeuN and cleaved caspase-3 in coronal brain sections from IgG- and anti-TIM-3-treated H/I mice 24 h after injury. Scale bar, 50 μm. The graph shows the mean number of NeuN and cleaved caspase-3-stained cells per mm2. (f) Immunoblot detection of full-length PARP proteins in contralateral and ipsilateral cortex regions of control IgG- or anti-TIM-3-treated mice. The graph shows the relative levels of full-length PARP (116 kDa). Data represent the mean±s.d. from at least three independent experiments. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25790768), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse TIM-3 by Immunohistochemistry
Blocking TIM-3 significantly reduces brain injury after hypoxia-ischaemia.(a) Representative images of TTC-stained brain slices from H/I mice treated with 100 μg of IgG (n=12) or anti-TIM-3 antibody (n=12). The infarct volume was quantified with Image J analyser and expressed as a percentage of the damaged ipsilateral hemisphere. (b) Representative magnetic resonance images (MRIs) from TIM-3-antibody-treated mice (n=4) and IgG-treated mice (n=4) at 24 h post-H/I. (c) Representative T2 images from TIM-3-antibody-treated mice (n=4) and IgG-treated mice (n=4) after H/I. (d) The extent of the oedema formation was obtained from the T2-weighted MRI images and ADC map. (e) Representative confocal microscopic images of immunohistochemical staining for NeuN and cleaved caspase-3 in coronal brain sections from IgG- and anti-TIM-3-treated H/I mice 24 h after injury. Scale bar, 50 μm. The graph shows the mean number of NeuN and cleaved caspase-3-stained cells per mm2. (f) Immunoblot detection of full-length PARP proteins in contralateral and ipsilateral cortex regions of control IgG- or anti-TIM-3-treated mice. The graph shows the relative levels of full-length PARP (116 kDa). Data represent the mean±s.d. from at least three independent experiments. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25790768), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse TIM-3 by Immunohistochemistry
Blocking TIM-3 significantly reduces brain injury after hypoxia-ischaemia.(a) Representative images of TTC-stained brain slices from H/I mice treated with 100 μg of IgG (n=12) or anti-TIM-3 antibody (n=12). The infarct volume was quantified with Image J analyser and expressed as a percentage of the damaged ipsilateral hemisphere. (b) Representative magnetic resonance images (MRIs) from TIM-3-antibody-treated mice (n=4) and IgG-treated mice (n=4) at 24 h post-H/I. (c) Representative T2 images from TIM-3-antibody-treated mice (n=4) and IgG-treated mice (n=4) after H/I. (d) The extent of the oedema formation was obtained from the T2-weighted MRI images and ADC map. (e) Representative confocal microscopic images of immunohistochemical staining for NeuN and cleaved caspase-3 in coronal brain sections from IgG- and anti-TIM-3-treated H/I mice 24 h after injury. Scale bar, 50 μm. The graph shows the mean number of NeuN and cleaved caspase-3-stained cells per mm2. (f) Immunoblot detection of full-length PARP proteins in contralateral and ipsilateral cortex regions of control IgG- or anti-TIM-3-treated mice. The graph shows the relative levels of full-length PARP (116 kDa). Data represent the mean±s.d. from at least three independent experiments. Image collected and cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/25790768), licensed under a CC-BY license. Not internally tested by R&D Systems.Detection of Mouse TIM-3 by Immunohistochemistry
TIM-3 is highly expressed in hypoxic brain regions of a H/I mouse model.(a) TIM-3 transcript levels were examined in brain tissues from the contralateral cortex (C, boxed region) and ischaemic ipsilateral cortex (I, boxed region) of mouse model 24 h after H/I. The RT–PCR products were quantified with Image J and normalized with respect to the expression of actin. The HIF-1 alpha transcript level represents a positive control for hypoxia. The right panel shows representative TTC staining of three brain sections from the H/I mice. (b) Representative western blot analyses of the TIM-3 and HIF-1 alpha proteins (n=3). Relative levels of TIM-3 are shown as the mean±s.d. from three independent experiments. (c) Contralateral and ipsilateral cortical regions of coronal sections from the H/I mice were subjected to immunohistochemistry using an anti-TIM-3 antibody, and the number of TIM-3-expressing cells per mm2 was counted. (d) Immunohistochemistry was performed on brain sections from the H/I mice using anti-TIM-3 and hypoxyprobe-1 (red, to detect hypoxic regions). Scale bars, 50 μm ( × 20); 50 μm ( × 40). (e,f) Brain cells were isolated from the ipsilateral and contralateral hemispheres of three mice per group, processed for simultaneous detection of TIM-3 plus Iba-1 (e) or GFAP (f), and analysed by FACS. The results are presented as relative TIM-3 levels in the indicated gated populations, as determined from three independent experiments. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/25790768), licensed under a CC-BY license. Not internally tested by R&D Systems.Applications for Mouse TIM‑3 Antibody
CyTOF-ready
Flow Cytometry
Sample: HT‑2 mouse T cell line
Immunohistochemistry
Sample: Immersion fixed paraffin-embedded sections of mouse spleen
Western Blot
Sample: RAW 264.7 mouse monocyte/macrophage cell line
Flow Cytometry Panel Builder
Bio-Techne Knows Flow Cytometry
Save time and reduce costly mistakes by quickly finding compatible reagents using the Panel Builder Tool.
Advanced Features
- Spectra Viewer - Custom analysis of spectra from multiple fluorochromes
- Spillover Popups - Visualize the spectra of individual fluorochromes
- Antigen Density Selector - Match fluorochrome brightness with antigen density
Formulation, Preparation, and Storage
Purification
Reconstitution
Reconstitute at 0.2 mg/mL in sterile PBS. For liquid material, refer to CoA for concentration.
Formulation
Shipping
Stability & Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Calculators
Background: TIM-3
References
- Anderson, A.C. and D.E. Anderson (2006) Curr. Opin. Immunol. 18:665.
- Mariat, C. et al. (2005) Phil. Trans. R. Soc. B 360:1681.
- Meyers, J.H. et al. (2005) Trends Mol. Med. 11:362.
- Monney, L. et al. (2002) Nature 415:536.
- Sabatos, C.A. et al. (2003) Nat. Immunol. 4:1102.
- Geng, H. et al. (2006) J. Immunol. 176:1411.
- Sanchez-Fueyo, A. et al. (2003) Nat. Immunol. 4:1093.
- Khademi, M. et al. (2004) J. Immunol. 172:7169.
- Wiener, Z. et al. (2007) J. Invest. Dermatol. 127:906.
- van de Weyer, P.S. et al. (2006) Biochem. Biophys. Res. Commun. 351:571.
- Gielen, A.W. et al. (2005) J. Neuroimmunol. 164:93.
- Oikawa, T. et al. (2006) J. Immunol. 177:4281.
- Zhu, C. et al. (2005) Nat. Immunol. 6:1245.
- Koguchi, K. et al. (2006) J. Exp. Med. 203:1413.
- Frisancho-Kiss, S. et al. (2006) J. Immunol. 176:6411.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional TIM-3 Products
Product Documents for Mouse TIM‑3 Antibody
Certificate of Analysis
To download a Certificate of Analysis, please enter a lot or batch number in the search box below.
Note: Certificate of Analysis not available for kit components.
Product Specific Notices for Mouse TIM‑3 Antibody
For research use only
Citations for Mouse TIM‑3 Antibody
Customer Reviews for Mouse TIM‑3 Antibody
There are currently no reviews for this product. Be the first to review Mouse TIM‑3 Antibody and earn rewards!
Have you used Mouse TIM‑3 Antibody?
Submit a review and receive an Amazon gift card!
$25/€18/£15/$25CAN/¥2500 Yen for a review with an image
$10/€7/£6/$10CAN/¥1110 Yen for a review without an image
Submit a review
Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
- 7-Amino Actinomycin D (7-AAD) Cell Viability Flow Cytometry Protocol
- Antigen Retrieval Protocol (PIER)
- Antigen Retrieval for Frozen Sections Protocol
- Appropriate Fixation of IHC/ICC Samples
- Cellular Response to Hypoxia Protocols
- Chromogenic IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Chromogenic Immunohistochemistry Staining of Frozen Tissue
- Detection & Visualization of Antibody Binding
- Extracellular Membrane Flow Cytometry Protocol
- Flow Cytometry Protocol for Cell Surface Markers
- Flow Cytometry Protocol for Staining Membrane Associated Proteins
- Flow Cytometry Staining Protocols
- Flow Cytometry Troubleshooting Guide
- Fluorescent IHC Staining of Frozen Tissue Protocol
- Graphic Protocol for Heat-induced Epitope Retrieval
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Graphic Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Graphic Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- IHC Sample Preparation (Frozen sections vs Paraffin)
- Immunofluorescent IHC Staining of Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Protocol
- Immunohistochemistry (IHC) and Immunocytochemistry (ICC) Protocols
- Immunohistochemistry Frozen Troubleshooting
- Immunohistochemistry Paraffin Troubleshooting
- Intracellular Flow Cytometry Protocol Using Alcohol (Methanol)
- Intracellular Flow Cytometry Protocol Using Detergents
- Intracellular Nuclear Staining Flow Cytometry Protocol Using Detergents
- Intracellular Staining Flow Cytometry Protocol Using Alcohol Permeabilization
- Intracellular Staining Flow Cytometry Protocol Using Detergents to Permeabilize Cells
- Preparing Samples for IHC/ICC Experiments
- Preventing Non-Specific Staining (Non-Specific Binding)
- Primary Antibody Selection & Optimization
- Propidium Iodide Cell Viability Flow Cytometry Protocol
- Protocol for Heat-Induced Epitope Retrieval (HIER)
- Protocol for Making a 4% Formaldehyde Solution in PBS
- Protocol for VisUCyte™ HRP Polymer Detection Reagent
- Protocol for the Characterization of Human Th22 Cells
- Protocol for the Characterization of Human Th9 Cells
- Protocol for the Preparation & Fixation of Cells on Coverslips
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Frozen Tissue Sections - Graphic
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation and Chromogenic IHC Staining of Paraffin-embedded Tissue Sections - Graphic
- Protocol for the Preparation and Fluorescent IHC Staining of Frozen Tissue Sections
- Protocol for the Preparation and Fluorescent IHC Staining of Paraffin-embedded Tissue Sections
- Protocol for the Preparation of Gelatin-coated Slides for Histological Tissue Sections
- Protocol: Annexin V and PI Staining by Flow Cytometry
- Protocol: Annexin V and PI Staining for Apoptosis by Flow Cytometry
- R&D Systems Quality Control Western Blot Protocol
- TUNEL and Active Caspase-3 Detection by IHC/ICC Protocol
- The Importance of IHC/ICC Controls
- Troubleshooting Guide: Fluorokine Flow Cytometry Kits
- Troubleshooting Guide: Immunohistochemistry
- Troubleshooting Guide: Western Blot Figures
- Western Blot Conditions
- Western Blot Protocol
- Western Blot Protocol for Cell Lysates
- Western Blot Troubleshooting
- Western Blot Troubleshooting Guide
- View all Protocols, Troubleshooting, Illustrated assays and Webinars